Qool Therapeutics, Inc., a Menlo Park, CA-based developer of non-invasive therapeutic hypothermia device for targeted temperature management and exercise recovery, closed a seed funding round of undisclosed amount.
An investor syndicate of angelMD led by orthopedic surgeon Michael Dillingham, MD, participated in the round.
Founded by entrepreneur and inventor Amir Belson, MD. Dr. Belson and led by CEO Beverly Huss, Qool Therapeutics aims to save hearts and minds with a non-invasive, field deployable, rapid therapeutic hypothermia system.
The Qool Therapeutics System is designed to deliver aerosolized frozen saline particles to the lungs. As the patient breaths in the tiny frozen saline particles, the system exploits the large surface area of the lungs with a direct path to the heart and brain for local cooling of these organs and later to a total body core temperature reduction.
While completing their seed funding round, the company is undergoing early animal studies using the therapeutic device and launching their Series A1 financing round.